Your browser doesn't support javascript.
loading
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
Montironi, Carla; Castet, Florian; Haber, Philipp K; Pinyol, Roser; Torres-Martin, Miguel; Torrens, Laura; Mesropian, Agavni; Wang, Huan; Puigvehi, Marc; Maeda, Miho; Leow, Wei Qiang; Harrod, Elizabeth; Taik, Patricia; Chinburen, Jigjidsuren; Taivanbaatar, Erdenebileg; Chinbold, Enkhbold; Solé Arqués, Manel; Donovan, Michael; Thung, Swan; Neely, Jaclyn; Mazzaferro, Vincenzo; Anderson, Jeffrey; Roayaie, Sasan; Schwartz, Myron; Villanueva, Augusto; Friedman, Scott L; Uzilov, Andrew; Sia, Daniela; Llovet, Josep M.
Afiliação
  • Montironi C; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Castet F; Pathology Department & Molecular Biology CORE, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Haber PK; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Pinyol R; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Torres-Martin M; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Torrens L; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Mesropian A; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Wang H; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Puigvehi M; Sema4, Stamford, Connecticut, USA.
  • Maeda M; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Leow WQ; Hepatology Section, Gastroenterology Department, Consorci Parc de Salut Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Harrod E; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Taik P; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Chinburen J; Department of Anatomical Pathology, Singapore General Hospital, Singapore.
  • Taivanbaatar E; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Chinbold E; Royal Surrey County Hospital, Guildford, UK.
  • Solé Arqués M; University of Surrey, Guildford, UK.
  • Donovan M; Sema4, Stamford, Connecticut, USA.
  • Thung S; Hepato-Pancreatico-Biliary Surgery Department, National Cancer Center, Ulaanbaatar, Mongolia.
  • Neely J; Hepato-Pancreatico-Biliary Surgery Department, National Cancer Center, Ulaanbaatar, Mongolia.
  • Mazzaferro V; Hepato-Pancreatico-Biliary Surgery Department, National Cancer Center, Ulaanbaatar, Mongolia.
  • Anderson J; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Roayaie S; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Schwartz M; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Villanueva A; Bristol-Myers Squibb, Princeton, New Jersey, USA.
  • Friedman SL; Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy.
  • Uzilov A; Bristol-Myers Squibb, Princeton, New Jersey, USA.
  • Sia D; Department of Surgery, White Plains Hospital Center, White Plains, New York, USA.
  • Llovet JM; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Gut ; 72(1): 129-140, 2023 01.
Article em En | MEDLINE | ID: mdl-35197323
ABSTRACT

OBJECTIVE:

We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy.

DESIGN:

We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients.

RESULTS:

Our integrative analysis led to define (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture ~90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p<0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation. CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-ßcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes.

CONCLUSION:

We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Gut Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Gut Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha